"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
In controlled clinical trials, the total incidence of adverse reactions associated with the use of STATICIN (erythromycin topical solution 1.5%) was approximately 13%. These were dryness (7%), oiliness (2%), pruritus (2%), tenderness (2%), desquamation (2%), erythema (1%) and irritation (1%).
The following additional adverse reactions have been reported occasionally: peeling, generalized urticarial reactions and itching.
Read the Staticin (erythromycin topical solution 1.5%) Side Effects Center for a complete guide to possible side effects
No information provided.
Last reviewed on RxList: 2/3/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Staticin Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.